CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914.
To obtain selective antiprogestins, we have examined the in vitro antiprogestational/antiglucocorticoid properties of two novel compounds, CDB-4124 and the putative monodemethylated metabolite, CDB-4453, in transcription and receptor binding assays and compared them to CDB-2914 and mifepristone. All four antiprogestins bound with high affinity to rabbit uterine progestin receptors (PR) and recombinant human PR-A and PR-B (rhPR-A, rhPR-B) and were potent inhibitors of R5020-induced transactivation of the PRE2-tk-luciferase (PRE2-tk-LUC) reporter plasmid and endogenous alkaline phosphatase production in T47D-CO human breast cancer cells. None of these compounds exhibited agonist activity in these cells. Induction of luciferase activity was potentiated about five-fold by 8-Br-cAMP under basal conditions and to the same extent in the presence of the PR antagonists. Mifepristone bound to rabbit thymic glucocorticoid receptors (GR) with approximately twice the avidity of the CDB antiprogestins. Inhibition of GR-mediated transcription of PRE2-tk-LUC was assessed in HepG2 human hepatoblastoma cells. Mifepristone exhibited greater antiglucocorticoid activity than CDB-2914, 4124, and 4453, about 12-, 22-, and 185-fold, respectively. Thus, while there was a good correlation between binding to PR and functional activity of these antiprogestins, GR binding was not predictive of their glucocorticoid antagonist activity. In agreement with our in vivo results, CDB-4124 and CDB-4453, as well as CDB-2914, are potent antiprogestins in vitro, but show considerably less antiglucocorticoid activity than mifepristone.
Attardi
Barbara J
BJ
Molecular Endocrinology Laboratory, BIOQUAL, Inc., 9600 Medical Center Drive, Rockville, MD 20850, USA. battardi@bioqual.com
Burgenson
Janet
J
Hild
Sheri A
SA
Reel
Jerry R
JR
Blye
Richard P
RP
D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D004790:Enzyme Induction; D006727:Hormone Antagonists / Q000378:metabolism / Q000494:pharmacology*; D008156:Luciferases / Q000378:metabolism; D015735:Mifepristone / Q000378:metabolism / Q000494:pharmacology*; D009649:Norpregnadienes / Q000378:metabolism / Q000494:pharmacology*; D010957:Plasmids; D011372:Progestins / Q000037:antagonists & inhibitors*; D011817:Rabbits; D051381:Rats; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism; D011965:Receptors, Glucocorticoid / Q000235:genetics / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000235:genetics / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D015533:Transcriptional Activation; D014162:Transfection; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000378:metabolism
D006727:Hormone Antagonists; D009649:Norpregnadienes; D011372:Progestins; D011944:Receptors, Androgen; D011965:Receptors, Glucocorticoid; D011980:Receptors, Progesterone; D011994:Recombinant Proteins; C461063:telapristone acetate; D015124:8-Bromo Cyclic Adenosine Monophosphate; D015735:Mifepristone; C461062:CDB-4453; C094854:ulipristal; D008156:Luciferases; D000469:Alkaline Phosphatase